26 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
core principles of modular innovation with protein-based cell programming focused on advanced targeting, pharmacological control and enhancement … Competition and Innovation Act amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
13 Feb 24
Regulation FD Disclosure
4:06pm
programs * BioNTech holds an option to co-fund and co-commercialize * *
A broad toolkit which is core to our strategy of modular innovation Viral
424B5
AUTL
Autolus Therapeutics plc
9 Dec 22
Prospectus supplement for primary offering
5:40pm
, refocusing such programs towards innovation in the U.K. On July 21, 2022, draft legislation was published setting out, among other things, details … 2022.
Our Pipeline
Our product pipeline is built on our core principles of modular innovation with protein-based cell programming focused on advanced
424B5
AUTL
Autolus Therapeutics plc
8 Dec 22
Prospectus supplement for primary offering
4:10pm
intention to introduce further restrictions to the U.K. research and development relief programs, refocusing such programs towards innovation … product pipeline is built on our core principles of modular innovation with protein-based cell programming focused on advanced targeting, pharmacological
6-K
EX-99.4
j146o03bls zer
8 Nov 21
Securities Purchase Agreement
5:28pm
424B5
o9pjxameziq1zllrph
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
yudh8n
6 Aug 21
Shelf registration (foreign)
2:30pm
6-K
EX-1
1g12iuynx ukay9
30 Jun 21
Annual Report and Accounts
6:05am
424B5
t7s55kmm ypk47g3nxn
11 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
w4ef88d ob
8 Feb 21
Prospectus supplement for primary offering
5:27pm
424B5
jya92k0
18 Sep 20
Prospectus supplement for primary offering
8:01am
6-K
EX-1
v7ffb1
26 May 20
Current report (foreign)
4:31pm
424B5
xlhzjt3
24 Jan 20
Prospectus supplement for primary offering
4:11pm
424B5
audg0zu5pie8o50iju
22 Jan 20
Prospectus supplement for primary offering
5:30pm
424B4
62gv31a
11 Apr 19
Prospectus supplement with pricing info
4:10pm
F-1
ebkhxf3rgeldfyfcs yq
8 Apr 19
Registration statement (foreign)
4:34pm
20-F
dozmn8rn9
23 Nov 18
Annual report (foreign)
12:00am